Perioperative chemotherapy is a standard treatment for patients with muscle-invasive bladder carcinoma undergoing radical cystectomy; however, direct comparisons of neoadjuvant and adjuvant chemotherapy are lacking.
Evidence-based data and implementation into daily clinical practice favor neoadjuvant chemotherapy; nevertheless, neoadjuvant chemotherapy is still underused in daily practice compared to adjuvant chemotherapy. If neoadjuvant chemotherapy has not been used and patients are fit enough to receive cisplatin, adjuvant chemotherapy should be considered in patients with pT3-pT4 and/or lymph node metastases.
Written by:
Ohlmann CH, De Santis M Are you the author?
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrberger Straße, 66424, Homburg/Saar, Deutschland,
(Article in German)
Reference: Urologe A. 2013 Nov;52(11):1534-8, 1540
doi: 10.1007/s00120-013-3249-7
http://www.ncbi.nlm.nih.gov/pubmed/24197083
PubMed Abstract
PMID: 24197083
UroToday.com Bladder Cancer Section
